Optiscan Imaging Limited (AU:OIL) has released an update.
Optiscan Imaging Ltd has announced the successful completion of their telepathology platform’s beta testing phase, in partnership with Prolucid Technologies. This innovative platform integrates Optiscan’s confocal imaging tech to enable real-time, remote collaboration for patient imaging, potentially revolutionizing digital pathology especially for remote areas. The company is now focused on developing a commercial version of the platform to enhance medical decision-making and patient care globally.
For further insights into AU:OIL stock, check out TipRanks’ Stock Analysis page.
